Boston, MA 03\/25\/2014 (wallstreetpr) –\u00a0BG Medicine, Inc. (NASDAQ:BGMD)<\/b> shares are up to a new 52-week high in the current session. The shares were up almost 26 percent by 11:30 a.m. EDT. The gain in the stock can be linked to the bullish rating which analysts at Ladenburg Thalmann issued on the stock. The analysts hoisted their target price on the shares of the life sciences company from $1.50 to $2.40. That marked the biggest price objective leap in the stock in the past four weeks. The Ladenburg Thalmann\u2019s price object suggests potential price upside of more than 41 percent from the previous closing price. The positive price adjustment supported shares of the company to climb even higher having been powered by widely encouraging quarterly earnings released last week. The company reported net loss per share of 6 cents, beating the expectation of 12 cents net loss per share. Revenue also topped consensus view, coming in at $1.15 million over $1.10 million which analysts modeled for the quarter. Analysts expect the company to suffer loss per share of 27 cents in the current fiscal year.<\/p>\n
\u00a0Galectin Therapeutics Inc. (NASDAQ:GALT)<\/b> has announced release of important trial data for its drug candidate target for treatment of cancer and fibrosis. A press release issued Tuesday, March 25, the company said it will reveal Phase I clinical data examining safety, tolerability and efficacy of GR-MD-02 in fatty liver conditions. The results of the study which enlisted a first cohort of eight patients will be released next Monday, March 31. The drug candidate whose Phase 1 trial results are coming next week was tried in single and multiple doses in the selected patients to capture its tolerability and safety. On April 1, a day after the release of the study results, Galectin Therapeutics Inc. (NASDAQ:GALT) said its CEO Peter G. Traber will lead a conference call, which will involve fielding questions from participants.<\/span>\u00a0<\/b><\/p>\n 22nd Century Group Inc (NYSEMKT:XXII)<\/b> shares are in a big breakout today, trading above average volume. The transition from OTC listing to NYSE is having its impact on the stock and all that is positive. Once viewed as a falling knife which everyone tried to avoid, the stock has completed its fall \u2013 at least it doesn\u2019t look able to fall any more. And in that floor position, now is the right time to make a pick because things can only get better from here. 22nd Century Group Inc (NYSEMKT:XXII) is a biotech company that is involved in the making of low-tar cigarettes and smoking withdrawal products. The company has been trading on NYSE since March 11.<\/p>\n","protected":false},"excerpt":{"rendered":" Boston, MA 03\/25\/2014 (wallstreetpr) –\u00a0BG Medicine, Inc. (NASDAQ:BGMD) shares are up to a new 52-week high in the current session. The shares were up almost […]<\/p>\n","protected":false},"author":32,"featured_media":18044,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5456,2350,5130,2351,5131,5457],"stock_ticker":[],"class_list":["post-18043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-22nd-century-group-inc-nysemktxxii","tag-bg-medicine-inc-nasdaqbgmd","tag-galectin-therapeutics-inc-nasdaqgalt","tag-nasdaqbgmd","tag-nasdaqgalt","tag-nysemktxxii","entry"],"acf":[],"yoast_head":"\n